Used in the field of oncology, BAY-850 functions as a selective inhibitor targeting KRAS protein mutations involved in cancer cell proliferation. Its primary application is in preclinical research, where it is studied for its potential to inhibit tumor growth and metastasis, particularly in cancers associated with KRAS mutations, which are challenging targets in current treatments. Researchers utilize it to explore its efficacy in various cancer models, aiming to develop targeted therapies for malignancies resistant to conventional treatments. Additionally, it is employed in biochemical assays to understand the mechanisms of action of its target proteins, contributing to the advancement of precision medicine in cancer therapy. It is currently in preclinical testing stages to evaluate safety and efficacy for potential future clinical applications.